What factors drove the changes in Nuvation Bio's revenue and profit?

What is the revenue and EPS growth rate for Nuvation Bio year over year?

What were the key takeaways from Nuvation Bio's earnings call?

What does Nuvation Bio do and what are its main business segments?

What is the market's earnings forecast for Nuvation Bio next quarter?

What is Nuvation Bio's gross profit margin?

What is Nuvation Bio's latest dividend and current dividend yield?

Did Nuvation Bio beat or miss consensus estimates last quarter?

- **IBTROZI Launch Success**: 432 new patients in 2025, 6x faster growth than prior TKIs, with 50-month median response in first-line.
- **Financial Strength**: $529M cash, $15.7M Q4 net product revenue, 25% gross to net rate, $60M Eisai upfront.
- **Pipeline Momentum**: Safusidenib Phase III (2029 readout), DDC platform retooled, and 2026 patient starts signaling first-line expansion.

**【CEO Summary Section】**
- Achieved FDA approval for IBTROZI in June 2025, treating 432 new patients by year-end, including 216 in Q4. Patient starts grew 6x faster than prior ROS1 TKI launches.
- IBTROZI demonstrated a 50-month median duration of response in TKI-naive patients and 66% intracranial response rate in second-line settings. 75% of discontinuations were from later-line patients.
- Launch momentum driven by first-line adoption, with 1,000+ TKI-experienced patients captured, positioning for long-term revenue growth.

**【CFO Financial Commentary】**
- Q4 2025 total revenue: $41.9M (including $15.7M IBTROZI net product revenue). Full-year 2025 revenue: $62.9M.
- Gross to net rate ~25%, reflecting broad payer coverage. Eisai partnership brought $60M upfront, with potential $140M in milestones and high-teens royalties.
- 2025 R&D/Sales & Marketing expenses: $115.1M/$151.6M, ending cash balance: $529.2M.

**【Q&A Highlights】**
- 2026 revenue guidance: Consensus $150M achievable via first-line adoption, despite Q1 seasonality. 200+ Q1 patient starts suggest continued momentum.
- Safusidenib Phase III (SIGMA) targeting 300 high-risk glioma patients, with 2029 PFS readout. Non-pivotal cohort for grade 3 oligodendroglioma (40 patients) may support accelerated approval if ORR >20%.
- DDC platform: NUV-1511 discontinued due to inconsistent responses, but lessons applied to next-generation candidates (updates expected Q4 2026).

Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript

- **IBTROZI Launch Success**: 204 new patients in Q3 (15/week), 50-month DOR in TKI-naive patients, surpassing competitor performance. 
- **Financial Strength**: $13.1M Q3 revenue, $549M cash, no guidance but $55M annualized run rate from Q3 patients. 
- **Strategic Wins**: Japan approval with $25M milestone, advanced Europe partnership, avoided $100M study cost. 
- **Pipeline Momentum**: TRUST-IV adjuvant trial initiated, safusidenib high-grade glioma trial on track, NUV-1511 data pending. 
- **Market Leadership**: 80% payer coverage, 98% territory engagement, fastest ROS1 launch in history. 


**【CEO Summary Section】**
- Launched IBTROZI in Q3 2025, achieving 204 new patient starts (15/week), surpassing competitor Augtyro's first 3-month performance (34 patients). 
- Updated data shows median duration of response (DOR) of 50 months in TKI-naive patients, up from 44 months. 
- Submitted supplemental NDA for label update with new DOR data and planning 2026 medical conference update.
- TRUST-IV Phase III study initiated for adjuvant therapy in early-stage ROS1+ NSCLC.
- Secured Japan regulatory approval and expects reimbursement approval Q4 2025 with $25M milestone payment.

**【CFO Financial Commentary】**
- Q3 2025 total revenue: $13.1M (including $7.7M net product revenue from IBTROZI). 
- Gross to net ratio ~20%, stable with 80% payer coverage. 
- Cash balance: $549M, sufficient for operations through profitability. 
- No guidance on net revenue but 204 Q3 patients represent $55M annualized run rate. 
- Avoided $100M head-to-head study cost by focusing on high-grade glioma trial. 
- European partnership discussions advanced, potential Q4 2025 update. 

**【Commercial Update】**
- 98% of 47 sales territories engaged, 80% payer coverage, 75% academic/community center prescriptions. 
- Free trial program converts patients in weeks, highlighting IBTROZI's tolerability. 
- 50% of new patients in second-line due to competitor limitations; expect shift to first-line as durability data solidifies. 
- Potential 16,000+ patients by Q4 2029 based on 50-month DOR and RNA testing expansion. 

**【Q&A Highlights】**
- No sales guidance; Q3 2025 net revenue growth driven by new patients, not channel stocking. 
- Market share leadership confirmed by 5x faster patient starts vs. Augtyro. 
- Japan reimbursement approval imminent, Europe partnership details Q4 2025. 
- Safusidenib high-grade glioma trial completion expected 2029; no low-grade head-to-head study due to cost. 
- NUV-1511 Phase I data update pending, potential new modality in targeted therapy. 


Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript

- **IBTROZI Launch Success**: 70 patients in 7 weeks, 58% payer coverage, and NCCN preferred status highlight strong early adoption.
- **Financial Strength**: $607M cash, $4.8M Q2 revenue, and $25M Japan milestone position company for sustained growth.
- **Pipeline Potential**: Safusidenib's 33% low-grade glioma ORR and DDC platform expansion create long-term opportunities.
- **Market Expansion**: RNA testing adoption could expand ROS1+ NSCLC addressable market by 30%, driven by IBTROZI's 4-year DOR.

**【CEO Summary Section】**
- **IBTROZI Launch Momentum**: 70 patients on therapy within 7 weeks of FDA approval (June 11), with 2+ new patients/day in business days. 90% of patients are new starts post-approval, not from early access programs.
- **Market Leadership**: NCCN guidelines added IBTROZI as preferred agent for ROS1+ NSCLC in all lines of therapy, citing its 89% ORR and 4-year median DOR. 58% of payer lives covered as of July.
- **Competitive Differentiation**: 80% of top 10 accounts prescribing IBTROZI; 75% of 47 sales territories with prescriptions. Early adoption in both first-line (40% of patients) and second-line (60%), including switches from crizotinib due to tolerability or CNS activity.
- **Pipeline Updates**: Safusidenib Phase II trial modified to maintenance therapy in high-grade glioma; NUV-1511 DDC platform Phase I data expected later this year. Japan partner approval for taletrectinib expected to trigger $25M milestone.

**【CFO Financial Commentary】**
- **Q2 2025 Financials**: Total revenue $4.8M (includes $1.2M IBTROZI net sales). R&D expenses $27.4M, SG&A $38.5M (commercial build-out). Cash balance $607.7M post-Sagard financing ($200M received, $50M available).
- **Revenue Model**: Focus on new patient starts (70 as of July) over channel stocking. Free Trial Program patients expected to convert to commercial sales in 2nd month.

**【Q&A Highlights】**
- **Patient Growth Rate**: August pace ~3 patients/day, up from 2/day in July. Early data shows ~40% first-line, 60% second-line use, but full breakdown unavailable due to specialty pharmacy anonymization.
- **RNA Testing Adoption**: Increasing recognition of RNA's superior sensitivity for ROS1 detection (~30% more cases). Nuvation expects academic centers to lead adoption, but timeline uncertain.
- **Safusidenib Strategy**: FDA discussions on registrational trials for both low-grade (ORR 33%) and high-grade (ORR 17%) glioma. Maintenance trial design aims to leverage prolonged DOR.
- **Japan Milestone**: $25M taletrectinib approval payment to be recognized as one-time revenue upon regulatory approval later this year.

Nuvation Bio Inc. (NUVB) Q2 2025 Earnings Call Transcript

- **Taletrectinib PDUFA Date Confirmed**: June 23, 2025, with strong clinical data (89% ORR, 46-month PFS) positioning as best-in-class ROS1 inhibitor.
- **CNS Activity Standout**: 77% intracranial ORR in first-line, addressing unmet need for brain metastasis management.
- **Pipeline Momentum**: Safusidenib moving to pivotal trials, NUV-1511 Phase 1 data expected, and $250M non-dilutive financing secured.
- **Commercial Readiness**: 47 oncology account managers, patient support programs, and $461.7M cash runway ensure launch execution.


**【CEO Opening Remarks】**
- Taletrectinib's FDA PDUFA date set for June 23, 2025, with all inspections completed successfully.
- Clinical data highlights: 89% ORR, 46-month median PFS, and 44-month DOR in first-line ROS1+ NSCLC.
- Differentiated CNS activity: 77% intracranial ORR in first-line, 66% in second-line settings.
- Favorable safety profile: 6.5% discontinuation rate, low-grade AE management.
- Pipeline expansion: Safusidenib (IDH1 inhibitor) moving to pivotal trials, NUV-1511 (drug conjugate) in Phase 1, and NUV-868 (BD2-selective BET inhibitor) showing target selectivity.

**【CFO Financial Update】**
- Q1 2025 R&D expenses: $24.6M (taletrectinib, safusidenib, NUV-1511, NUV-868).
- SG&A expenses: $35.4M (commercial build-out, medical education, patient support).
- Cash position: $461.7M (pre-Sagard financing), with $250M non-dilutive capital secured.
- Launch readiness: 47 oncology account managers, field access team, and patient support programs in place.

**【Q&A Key Points】**
- **Market Strategy**: Focus on early diagnosis and first-line use, leveraging NCCN guideline updates favoring ROS1 TKIs over IO-chemo.
- **FDA Dialogue**: High engagement with agency, confident in data package strength.
- **Pipeline Updates**: Safusidenib Phase 2 data expected H2 2025, potential pivotal trials for low-grade and high-grade glioma.
- **CNS Disease Prevention**: Long PFS (46 months) suggests delayed resistance, reducing need for late-line CNS-targeted therapies.
- **Financial Flexibility**: Sagard financing covers launch costs, preserving capital for pipeline advancement.


Actual	-0.12	-0.09	-0.11	-0.12	-0.1	-0.16	-0.12	-0.1	-0.1	-0.09	-0.09	-0.06	-0.07	-1.89	-0.15	-0.15	-0.16	-0.17	-0.16	-0.11
Forecast	-0.0801	-0.0985	-0.1053	-0.1157	-0.1389	-0.1329	-0.14	-0.1186	-0.1001	-0.1123	-0.105	-0.0993	-0.0917	-0.0585	-0.126	-0.1283	-0.15	-0.17	-0.1687	-0.089
Surprise	-49.81%	+8.63%	-4.46%	-3.72%	+28.01%	-20.39%	+14.29%	+15.68%	+0.10%	+19.86%	+14.29%	+39.58%	+23.66%	-3130.77%	-19.05%	-16.91%	-6.67%	0.00%	+5.16%	-23.60%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	0	1.44M	727.00K	5.71M	3.08M	4.83M	13.12M	41.87M
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	500.00K	416.67K	6.61M	37.81M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+516.80%	+1059.92%	+98.50%	+10.71%

NUVB

NUVB fundamentals

NUVB Q4 2025 Earnings

Earnings Call

You can ask Aime

NUVB

NUVB fundamentals

NUVB Q4 2025 Earnings

Earnings Call

NUVB Earnings Call Summary for Q4/20254:30 PM on Mar 2, 2026

NUVB Earnings Call Summary for Q3/20254:30 PM on Nov 3, 2025

NUVB Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

NUVB Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

NUVB Earnings Call Summary for Q4/2024 Apr 3, 2026

You can ask Aime